|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigated the association between PTGS2 expression and prognosis in patients with oesophageal adenocarcinoma.
|
30408225 |
2019 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mean standardised uptake value (SUV<sub>mean</sub>) on PET imaging is associated with COX-2 expression in oesophageal adenocarcinoma.
|
30982333 |
2019 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).
|
24206575 |
2013 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to evaluate expression, prognostic value and correlation between COX-2 and VEGF expression in esophageal adenocarcinoma (EAC).
|
22258871 |
2012 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Indomethacin and parecoxib inhibit the growth of human esophageal adenocarcinoma xenografts in nude mice, which suggests a potential role for NSAIDs or selective COX-2 inhibitors for EAC chemotherapy.
|
21971589 |
2012 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of cyclooxygenase-2 (COX-2) and chronic inflammation in the progression of BE toward adenocarcinoma of the esophagus has not been extensively studied in experimental models of BE in animals and in human subjects.
|
20814068 |
2010 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a population-based case-control study, we examined associations of the COX-2 8473 T>C and iNOS Ser(608) Leu (C>T) polymorphisms with risk of esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis.
|
18349295 |
2008 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma.
|
17581270 |
2007 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also correlated COX-2 and FGF-2 expression with clinico-pathologic findings and outcome in a well-characterized series of surgically resected EADC tissues.
|
17477358 |
2007 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells.
|
17403674 |
2007 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Previous studies from our laboratory and others have suggested that increased expression of cox-2 is important in the genesis of esophageal adenocarcinoma.
|
16550596 |
2006 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Higher levels of COX-2 expression are associated with poor clinico-pathologic features and poor survival in patients with oesophageal adenocarcinoma.
|
16712734 |
2006 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene expression data suggest that pharmacologic inhibition of COX-2 and VEGF may be useful adjuncts in targeted therapy for esophageal adenocarcinoma.
|
16702519 |
2006 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expressions of both COX-2 and EGFR increased along with the progression from BE to esophagus adenocarcinoma (EAC).
|
16521222 |
2006 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Met expression, phosphorylation, and the effect of COX-2 inhibition on expression were examined in EA cell lines.
|
15720819 |
2005 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our study was initiated to test whether expression of COX isoforms (COX-1 and COX-2) is linked to expression of potent inducers of angiogenesis [vascular endothelial growth factor (VEGF)-A] and lymphangiogenesis (VEGF-C) in esophageal adenocarcinoma.
|
15958546 |
2005 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis revealed significantly more nuclear accumulation of beta-catenin and overexpression of cyclooxygenase-2 in patients with esophageal adenocarcinoma, compared with patients with cardiac carcinoma.
|
15623628 |
2004 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results confirm the important role of Cox-2 amplification in the pathogenesis of esophageal adenocarcinoma, but the unexpected down-regulation of Cox-1 raises questions about its role in carcinogenesis.
|
15585388 |
2004 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
|
15205347 |
2004 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The COX-2 enzyme has been reported to be over-expressed in premalignant and malignant states, including in Barrett's esophagus and esophageal adenocarcinoma.
|
14641306 |
2003 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 inhibition induces apoptosis and blocks proliferation in COX-2-expressing esophageal adenocarcinoma cells in vitro, and blocks angiogenesis in both in vivo and in vitro models.
|
12060038 |
2002 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
CTD_human |
Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model.
|
12507933 |
2002 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.
|
11005569 |
2001 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to determine whether selective inhibition of COX-2 by NS-398 would alter the rates of cell growth and apoptosis in human Barrett's-associated esophageal adenocarcinoma cell lines.
|
11059772 |
2000 |